このページの翻訳は実験的なもので、現在開発中です。お待ちしております

GoodRx Holdings マネジメント

マネジメント基準チェック /24

GoodRx Holdings'の CEO はScott Wagnerで、 Apr2023年に任命され、の在任期間は 1.33年です。の年間総報酬は$ 10.14Mで、 5%給与と95%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.088%を直接所有しており、その価値は$ 2.54M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と7年です。

主要情報

Scott Wagner

最高経営責任者

US$10.1m

報酬総額

CEO給与比率	5.0%
CEO在任期間	1.4yrs
CEOの所有権	0.1%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	7.1yrs

経営陣の近況

Recent updates

GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

Sep 22

GoodRx Q2 Earnings Preview

Jul 31

GoodRx Holdings (NASDAQ:GDRX) Could Easily Take On More Debt

Jul 12

GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 30% Price Boost Is Out Of Tune With Revenues

Jun 09

GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 07

Is GoodRx Holdings, Inc. (NASDAQ:GDRX) Trading At A 24% Discount?

Mar 01

GoodRx Holdings (NASDAQ:GDRX) Has A Rock Solid Balance Sheet

Feb 12

GoodRx: Cost Saving Is A Strong Value Proposition To Consumers

Jan 23

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Jan 22

GoodRx Stock Spikes After Receiving A Strong Dose Of Performance

Jan 11

What Is GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Share Price Doing?

Dec 02

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Sep 12

An Intrinsic Calculation For GoodRx Holdings, Inc. (NASDAQ:GDRX) Suggests It's 41% Undervalued

Jul 14

GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

May 27

Some Confidence Is Lacking In GoodRx Holdings, Inc. (NASDAQ:GDRX) As Shares Slide 27%

May 05

Investors Give GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares A 27% Hiding

May 05

Is There An Opportunity With GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 45% Undervaluation?

Mar 23

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Feb 07

GoodRx Holdings (NASDAQ:GDRX) Could Be Struggling To Allocate Capital

Nov 02

GoodRx laying off 140 employees, 16% of workforce

Aug 31

GoodRx: Trending Positive, But Not A Buy Yet

Aug 25

CEO報酬分析

GoodRx Holdings の収益と比較して、Scott Wagner の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$59m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$10m	US$512k	-US$9m

報酬と市場: Scottの総報酬 ($USD 10.14M ) は、 US市場 ($USD 6.74M ) の同規模の企業の平均を上回っています。

報酬と収益: Scottの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Scott Wagner (53 yo)

1.4yrs

在職期間

US$10,144,526

報酬

Mr. Scott W. Wagner serves as Interim Chief Executive Officer at GoodRx Holdings, Inc. since April 25, 2023 and serves as its Principal Operating Officer since February 15, 2024. He serves as Head of Strat...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Trevor Bezdek	Co-founder & Chairman of the Board	13yrs	US$811.53k	1.42% $ 36.1m
Scott Wagner	Interim CEO & Principal Operating Officer	1.4yrs	US$10.14m	0.097% $ 2.5m
Douglas Hirsch	Co-founder	13yrs	US$784.86k	1.42% $ 36.1m
Karsten Voermann	Chief Financial Officer	4.5yrs	US$902.24k	0.072% $ 1.8m
Romin Nabiey	Chief Accounting Officer	2.4yrs	US$2.58m	0.019% $ 486.6k
Bansi Nagji	President of Healthcare	4.3yrs	US$4.91m	0.065% $ 1.7m
Mike Walsh	President & Executive VP of Prescription Marketplace	less than a year	データなし	データなし
Nitin Shingate	Chief Technology Officer	1.8yrs	データなし	データなし
Aubrey Reynolds	Director of Investor Relations	no data	データなし	データなし
Gracye Cheng	General Counsel & Secretary	no data	データなし	データなし
Andrew Slutsky	Chief Marketing Officer	1.2yrs	US$864.80k	0% $ 0
Vina Leite	Chief People Officer	2.3yrs	データなし	データなし

2.4yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: GDRXの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Trevor Bezdek	Co-founder & Chairman of the Board	13yrs	US$811.53k	1.42% $ 36.1m
Douglas Hirsch	Co-founder	13yrs	US$784.86k	1.42% $ 36.1m
Gregory Mondre	Independent Director	5.9yrs	データなし	データなし
Dipanjan Deb	Independent Director	8.9yrs	データなし	データなし
Ian T. Clark	Director	less than a year	データなし	データなし
Agnes Rey-Giraud	Independent Director	8.3yrs	US$269.53k	0.079% $ 2.0m
Julie M. Bradley	Independent Director	4.1yrs	US$272.53k	0.025% $ 638.1k
Christopher Adams	Independent Director	8.9yrs	データなし	データなし
Simon Patterson	Director	less than a year	データなし	データなし
Kelly Kennedy	Independent Director	less than a year	US$448.63k	データなし

7.1yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: GDRXの取締役会は経験豊富であると考えられます ( 7年の平均在任期間)。

GoodRx Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Key Executive exercised options and sold US$276k worth of stock

Chief Accounting Officer recently sold US$535k worth of stock

Key Executive exercised options and sold US$308k worth of stock

GoodRx Holdings, Inc. Announces the Election of Ian T. Clark to its Board of Directors

Key Executive exercised options and sold US$280k worth of stock

Key Executive exercised options and sold US$306k worth of stock

Recent updates

GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

Key Executive exercised options and sold US$276k worth of stock

Chief Accounting Officer recently sold US$535k worth of stock

Key Executive exercised options and sold US$308k worth of stock

GoodRx Holdings, Inc. Revises Earnings Guidance for the Full Year 2024

GoodRx Q2 Earnings Preview

Boehringer Ingelheim and Goodrx Announce Exclusive Patient Affordability Initiative for Adalimumab-Adbm Injection, Boehringer's Biosimilar to Humira®

GoodRx Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

GoodRx Holdings (NASDAQ:GDRX) Could Easily Take On More Debt

GoodRx Holdings, Inc. Announces the Election of Ian T. Clark to its Board of Directors

Key Executive exercised options and sold US$280k worth of stock

GoodRx Launches New "Prescription Cost Tracker" to Spotlight Key Factors Driving Out-Of-Pocket Medication Costs in the U.S

Key Executive exercised options and sold US$306k worth of stock

GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 30% Price Boost Is Out Of Tune With Revenues

Returns On Capital At GoodRx Holdings (NASDAQ:GDRX) Paint A Concerning Picture

GoodRx Holdings, Inc Announces Board and Committee Changes

GoodRx: Encouraging Profit Stabilization (Rating Upgrade)

Price target increased by 7.5% to US$9.40

GoodRx Holdings, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

First quarter 2024 earnings released: US$0.003 loss per share (vs US$0.008 loss in 1Q 2023)

GoodRx Holdings, Inc., Annual General Meeting, Jun 06, 2024

Kessler Topaz Meltzer & Check, LLP Files A Securities Fraud Class Action Lawsuit Against GoodRX Holdings, Inc

GoodRx Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

GoodRx Holdings: Large TAM Continues To Support Growth

GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Price target increased by 15% to US$8.21

Is GoodRx Holdings, Inc. (NASDAQ:GDRX) Trading At A 24% Discount?

Goodrx Holdings, Inc. Provides Revenue Guidance for First Quarter 2024 and Fiscal Year 2024

GoodRx Holdings (NASDAQ:GDRX) Has A Rock Solid Balance Sheet

GoodRx: Cost Saving Is A Strong Value Proposition To Consumers

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Consensus EPS estimates upgraded to US$0.0037 loss

GoodRx Holdings, Inc. Announces Executive Changes

Consensus EPS estimates upgraded to US$0.0047 loss

GoodRx Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GoodRx Stock Spikes After Receiving A Strong Dose Of Performance

GoodRx Holdings, Inc. Revises Earnings Guidance for the Fourth Quarter and Year Ended December 31, 2023

GoodRx Holdings, Inc. Appoints Kelly J. Kennedy to Its Board of Directors

What Is GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Share Price Doing?

Chief Operating Officer exercised options and sold US$263k worth of stock

Interim Chief Executive Officer recently bought US$677k worth of stock

Consensus EPS estimates fall from profit to US$0.013 loss

Price target decreased by 11% to US$7.50

Goodrx Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

New minor risk - Shareholder dilution

GoodRx Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

GoodRx Launches Real-Time Benefit Check in Provider Mode to Offer Comprehensive Cost Information at the Point of Prescribing

Consensus EPS estimates increase by 59%

Chief Operating Officer exercised options and sold US$338k worth of stock

Price target increased by 18% to US$8.00

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Goodrx Holdings, Inc. Provides Revenue Guidance for the Third Quarter and Full Year 2023

New minor risk - Share price stability

An Intrinsic Calculation For GoodRx Holdings, Inc. (NASDAQ:GDRX) Suggests It's 41% Undervalued

GoodRx Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Goodrx Appoints Dorothy Gemmell as Chief Commercial Officer

Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX).

Goodrx Holdings, Inc. Announces Resignation of Jacqueline Kosecoff as Member of the Board, Effective June 30, 2023

Goodrx Holdings Notifies the Listing Qualifications Department of the Nasdaq Regarding Non Compliance with Nasdaq Listing Rule 5605(c)(2)(A)

GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

Chief Operating Officer exercised options and sold US$222k worth of stock

Consensus EPS estimates fall by 18%

Price target decreased by 7.1% to US$6.41

Consensus EPS estimates upgraded to US$0.03 loss, revenue downgraded

Goodrx Holdings, Inc. Provides Revenue Guidance for the Second Quarter and Full Year of 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

Some Confidence Is Lacking In GoodRx Holdings, Inc. (NASDAQ:GDRX) As Shares Slide 27%

Investors Give GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares A 27% Hiding

マネジメント基準チェック /24